Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Prostate Cancer: a Systematic Review with Meta-analysis

  • Wang, Kai (Department of Urology, Xinqiao Hospital, Third Military Medical University) ;
  • Peng, Hong-Ling (Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University) ;
  • Li, Long-Kun (Department of Urology, Xinqiao Hospital, Third Military Medical University)
  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The vascular endothelial growth factor (VEGF) mediates vasculogenesis and angiogenesis through promoting endothelial cell growth, migration and mitosis, and has involvement in cancer pathogenesis, progression and metastasis. However, the prognostic value of VEGF in patients with prostate cancer remains controversial. Objectives: The aim of our study was to evaluate the prognostic value of VEGF in prostate cancer, and summarise the results of related research on VEGF. Methods: In accordance with an established search strategy, 11 studies with 1,529 patients were included in our meta-analysis. The correlation of VEGF-expression with overall survival and progression-free survival was evaluated by hazard ratio, either given or calculated. Results: The studies were categorized by introduction of the author, demographic data in each study, prostate cancer-relatived information, VEGF cut-off value, VEGF subtype, methods of hazard ratio (HR) estimation and its 95% confidence interval (CI). High VEGF-expression in prostate cancer is a poor prognostic factor with statistical significance for OS (HR=2.32, 95%CI: 1.40-3.24). However, high VEGF-expression showed no effect on poor PFS (HR=1.30, 95%CI: 0.88-1.72). Using Begg's, Egger's test and funnel plots, we confirmed lack of publication bias in our analysis. Conclusion: VEGF might be regarded as a prognostic maker for prostate cancer, as supported by our meta-analysis. To achieve a more definitive conclusion enabling the clinical use of VEGF in prostate cancer, we need more high-quality interventional original studies following agreed research approaches or standards.

Keywords

References

  1. Banerjee S, Dowsett M, Ashworth A, Martin LA (2007). Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol, 4, 536-50.
  2. Barraclough H, Simms L, Govindan R (2011). Biostatistics primer: what a clinician ought to know: hazard ratios. J Thorac Oncol, 6, 978-82. https://doi.org/10.1097/JTO.0b013e31821b10ab
  3. Bates DO, Lodwick D, Williams B (1999). Vascular endothelial growth factor and microvascular permeability. Microcirculation, 6, 83-96. https://doi.org/10.1038/sj.mn.7300054
  4. Bok RA, Halabi S, Fei DT, et al (2001). Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res, 61, 2533-6.
  5. Brawley OW (2012). Prostate cancer epidemiology in the United States. World J Urol, 30, 195-200. https://doi.org/10.1007/s00345-012-0824-2
  6. Caine GJ, Lip GY, Stonelake PS, Ryan P, Blann AD (2004). Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost, 92, 185-90.
  7. Carmeliet P, Jain RK (2011). Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov, 10, 417-27. https://doi.org/10.1038/nrd3455
  8. Duque JL, Loughlin KR, Adam RM, et al (1999). Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology, 54, 523-7. https://doi.org/10.1016/S0090-4295(99)00167-3
  9. Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995). Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature, 376, 66-70. https://doi.org/10.1038/376066a0
  10. Fukuda H, Tsuchiya N, Narita S, et al (2007). Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer. Oncol Rep, 18, 1155-63.
  11. George DJ, Halabi S, Shepard TF, et al (2001). Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res, 7, 1932-6.
  12. Green MM, Hiley CT, Shanks JH, et al (2007). Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys, 67, 84-90. https://doi.org/10.1016/j.ijrobp.2006.08.077
  13. Jain L, Vargo CA, Danesi R, et al (2009). The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther, 8, 2496-508. https://doi.org/10.1158/1535-7163.MCT-09-0302
  14. Kaban K, Herbst RS (2002). Angiogenesis as a target for cancer therapy. Hematol Oncol Clin North Am, 16, 1125-71. https://doi.org/10.1016/S0889-8588(02)00047-3
  15. Kelly WK, Halabi S, Carducci M, et al (2012). Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol, 30, 1534-40. https://doi.org/10.1200/JCO.2011.39.4767
  16. Kowanetz M, Ferrara N (2006). Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res, 12, 5018-22. https://doi.org/10.1158/1078-0432.CCR-06-1520
  17. Kuniyasu H, Troncoso P, Johnston D, et al (2000). Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res, 6, 2295-308.
  18. Martin B, Paesmans M, Mascaux C, et al (2004). Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer, 91, 2018-25. https://doi.org/10.1038/sj.bjc.6602233
  19. Mori R, Dorff TB, Xiong S, et al (2010). The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate, 70, 1692-700. https://doi.org/10.1002/pros.21204
  20. Nassif AE, Tambara Filho R, Paula RX, Taguchi WS, Pozzobon HJ (2009). [Epidemiologic profile and prognostic factors in clinically localized prostate adenocarcinoma submitted to surgical treatment]. Rev Col Bras Cir, 36, 327-31. https://doi.org/10.1590/S0100-69912009000400010
  21. Peyromaure M, Camparo P, Badoual C, Descazeaud A, Dinh-Xuan AT (2007). The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy. BJU Int, 99, 1150-3. https://doi.org/10.1111/j.1464-410X.2007.06734.x
  22. Pili R, Rosenthal MA, Mainwaring PN, et al (2010). Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res, 16, 2906-14. https://doi.org/10.1158/1078-0432.CCR-09-3026
  23. Pradeep CR, Sunila ES, Kuttan G (2005). Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr Cancer Ther, 4, 315-21. https://doi.org/10.1177/1534735405282557
  24. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ (2004). Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol, 172, 910-4. https://doi.org/10.1097/01.ju.0000134888.22332.bb
  25. Ross RW, Galsky MD, Febbo P, et al (2012). Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer : A Prostate Cancer Clinical Trials Consortium trial. Cancer, 118, 4777-84. https://doi.org/10.1002/cncr.27416
  26. Shariat SF, Anwuri VA, Lamb DJ, et al (2004). Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol, 22, 1655-63. https://doi.org/10.1200/JCO.2004.09.142
  27. Shariat SF, Karam JA, Walz J, et al (2008). Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res, 14, 3785-91. https://doi.org/10.1158/1078-0432.CCR-07-4969
  28. Shijubo N, Kojima H, Nagata M, et al (2003). Tumor angiogenesis of non-small cell lung cancer. Microsc Res Tech, 60, 186-98. https://doi.org/10.1002/jemt.10257
  29. Sitohy B, Nagy JA, Dvorak HF (2012). Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res, 72, 1909-14. https://doi.org/10.1158/0008-5472.CAN-11-3406
  30. Svatek RS, Jeldres C, Karakiewicz PI, et al (2009). Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate, 69, 886-94. https://doi.org/10.1002/pros.20938
  31. Wang Q, Diao X, Sun J, Chen Z (2011). Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy. Urol Oncol.
  32. Weber DC, Tille JC, Combescure C, et al (2012). The prognostic value of expression of HIF1alpha, EGFR and VEGF-A, in localized prostate cancer for intermediate-and high-risk patients treated with radiation therapy with or without androgen deprivation therapy. Radiat Oncol, 7, 66. https://doi.org/10.1186/1748-717X-7-66
  33. West AF, O'Donnell M, Charlton RG, Neal DE, Leung HY (2001). Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer, 85, 576-83. https://doi.org/10.1054/bjoc.2001.1971
  34. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985). Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis, 27, 335-71. https://doi.org/10.1016/S0033-0620(85)80003-7
  35. Zilinberg K, Roosen A, Belka C, Ganswindt U, Stief CG (2012). [Management of prostate cancer]. MMW Fortschr Med, 154, 47-50.

Cited by

  1. Vascular Endothelial Growth Factor (VEGF) Gene Polymorphisms and Breast Cancer Risk in a Chinese Population vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2433
  2. Associations between vascular endothelial growth factor polymorphisms and prostate cancer risk: a meta-analysis vol.35, pp.2, 2014, https://doi.org/10.1007/s13277-013-1173-5
  3. Chitosan oligosaccharides in combination with Agaricus blazei Murill extract reduces hepatoma formation in mice with severe combined immunodeficiency vol.12, pp.1, 2015, https://doi.org/10.3892/mmr.2015.3454
  4. Diagnostic and Therapeutic Implications of the Vascular Endothelial Growth Factor Family in Cancer vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1677
  5. Is Volatile Anesthesia During Cancer Surgery Likely to Increase the Metastatic Risk? vol.54, pp.4, 2016, https://doi.org/10.1097/AIA.0000000000000115
  6. A Meta-Analysis of Vascular Endothelial Growth Factor for Nasopharyngeal Cancer Prognosis vol.8, pp.2234-943X, 2018, https://doi.org/10.3389/fonc.2018.00486
  7. Apparent diffusion coefficients in prostate cancer: correlation with molecular markers Ki-67, HIF-1α and VEGF vol.31, pp.3, 2018, https://doi.org/10.1002/nbm.3884